

Dr. Mukul Mohindra

M.S [Ortho], DNB, MNAMS
Dip. SICOT [Belgium]
FNB [Sports Medicine]
Fellowship in MIA, Athens [SICOT]

Consultant at CGHS Wing and CIO, Safdarjung Hospital and VMM College, New Delhi




OSTEOPOROSIS



A 48 years female comes with a report showing deficient Vitamin D levels. Likely diagnosis:

- A. Osteoporosis
- B. Osteomalacia
- C. Can be Both
- D. Information is insufficient to diagnose either







OSTEOPOROSIS

OSTEOMALACIA



Normal

O.Matrix

Mineral

Osteoporosis

O.Matrix

Mineral

Normal

O.Matrix

Mineral

Osteomalacia

O. Matrix

Mineral



CLASSIFICATION

Type I (Post menopausal): approximately 2–3% of the total bone is lost per year, mainly trabecular bone **Primary** Type II (Senile): Bone loss is from both cortical and trabecular bone and is approximately 0.5–1%/ year Generalized DRUGS Secondary DISEASES **HORMONES**



Q. Critical steroid dose that leads to Osteoporosis

- A. > 5 mg Prednisolone/ day for 6 weeks
- B. > 7.5 mg Prednisolone/ day for 2 months
- C. > 5 mg Prednisolone/ day for 6 weeks
- D. > 7.5 mg Prednisolone/ day for 3 months



RISK FACTORS



Diet and Nutrition

Activity level

Estrogen status

BMI







True for Osteoporotic fractures is all EXCEPT

- A. Stress fractures
- B. Insufficiency fractures
- C. Fragility fractures
- D. Pathological fractures



Table 2.13: The relation between bone quality and bone load in producing various types of fractures

Type	Bone quality	Load
Traumatic	Normal	Single large
Fatigue (stress)	Normal	Repetitive
Insufficiency (stress)	Abnormal (metabolic)	Minimal
Pathological	Abnormal (tumor)	Minimal



DIAGNOSIS

Blood parameters

X rays

Spine


Hip and Pelvis


Quantitative CT scan

Single Photon Absorptiometry



DEXA Scan





DEXA SCAN

WHO	
ORTHO	

(C) www.targetortho.com

Indication

Which of the following parameter can be reliably evaluated from DEXA Scan apart form BMD?

- A. Bone mass
- B. Fat content in body
- C. Body mass index
- D. Detect a stress fracture



TREATMENT

Table 15.3: Calcium preparations			
Salt	Elemental calcium (%)	Solubility	
Calcium carbonate	40	Insoluble	
Tricalcium phosphate	39	Insoluble	
Calcium citrate	21	Soluble	
Calcium lactate	18	Soluble	
Calcium gluconate	9	Soluble	

Table 15.4: Recommended calcium intake		
Age	Elemental calcium (mg/day)	
Infants	400-600	
1-10 years	800-1,200	
Adolescents	1,200-1,500	
Adults: men	1,200-1,500	
Women 19-24 years	1,200-1,500	
25-50 years	1,000	
>50 years	1,500	
Pregnant and lactating	1,500	

TEAECITONIN	VITAMIN D	CALCIUM
URTHU		
(C) www.targetortho.com		

Q. 62 years post menopausal female presented with questions regarding her new diagnosis of Osteoporosis. She has a fall 6 months back when she was bed ridden for 2 months and even put on warfarin. She has recovered but was diagnosed with osteoporosis then. Her DEXA has T score value of -2.6. Her past history includes Achlasia cardia for which she gets dilatations as needed. She is a known diabetic but well controlled. Her RFT, LFT, HbA1c, Vit D are WNL. Drug you will prefer to manage her osteoporosis?

- A. Zoledronic acid
- B. Alendronate
- C. Raloxifene
- D. Calcitonin
- E. HRT



Long term Bisphosphonate use

AFFs were first described by Odvina and colleagues in 2005

The American Society for Bone and Mineral Research (ASBMR) task force **gave definition** in 2010 (Shane et al.)

Revised in 2013: *To distinguish from ordinary osteoporotic femur fractures*

Major and Minor Criteria



Weight bearing should be limited for patients with incomplete fractures

Management includes intramedullary nailing for complete fractures + Alternative medications Teriparatide, an anabolic agent,

Atypical Femoral Fractures



AFFs

To satisfy the case definition of AFF, the fracture must be located along the femoral diaphysis from just distal to the lesser trochanter to just proximal to the supracondylar flare.

In addition, at least four of five Major Features must be present. None of the Minor Features is required but have sometimes been associated with these fractures.

Major features^a

The fracture is associated with minimal or no trauma, as in a fall from a standing height or less

The fracture line originates at the lateral cortex and is substantially transverse in its orientation, although it may become oblique as it progresses medially across the femur

Complete fractures extend through both cortices and may be associated with a medial spike; incomplete fractures involve only the lateral cortex

The fracture is noncomminuted or minimally comminuted

Localized periosteal or endosteal thickening of the lateral cortex is present at the fracture site ("beaking" or "flaring")

Minor features

Generalized increase in cortical thickness of the femoral diaphyses

Unilateral or bilateral prodromal symptoms such as dull or aching pain in the groin or thigh

Bilateral incomplete or complete femoral diaphysis fractures

Delayed fracture healing



In about 70% of patients, pain in the thigh or groin may be present for several weeks or months before the atypical femoral fracture occurs

Looser's Zones





ADD ONs

SERMs

Bone; Lipid- Agonist

Breast; Uterus- Antagonist

Anabolic steroids

Strontium

HRT



Estrogen: 0.625 mg/ day

Progesterone: 5 mg/ day

DOC in Post menopausal osteoporosis?



- A. Bisphosphonates
- B. Strontium
- C. HRT
- D. Teriperatide


MC side effects: Breast tenderness and headaches


Other Side effects: endometrial cancer, thromboembolic phenomena and risk of getting cholecystitis, increased risk of breast cancer (doubtful, not proven).

Adding progestin seemingly decreases this risk. Women receiving combination therapy can get withdrawal bleeding.



BISPHOSPHONATE RESISTANCE








Q. Which of the following drugs is not associated with Osteonecrosis of Jaw as a complication?

- A. Zolendronic Acid
- B. Denozumab
- C. Bevacizumab
- D. None of the above



SURGICAL TREATMENT



Original Indications

TOP UPs

VERTEBROPLASTY

DENOZUMAB

Some newer drugs IN LINE for osteoporosis:

—*Cathepsin-K inhibitors*: Odanacatib is a once weekly oral treatment for osteoporosis. It inhibits cathepsin-K, a cysteine protease expressed in osteoclasts which degrades type 1 collagen (not yet approved by FDA, phase 3 trial completed)

—Monoclonal antibody to sclerostin (Romosozumab): Sclerostin, an osteocyte-secreted protein negatively regulates osteoblasts and inhibits bone formation through the LRP5/Wnt signaling pathway. Romosozumab has shown promising results in phase 2 trials.

FRAX TOOL Fracture Risk Assessment Tool


The University of Sheffield launched the FRAX tool in 2008

It was developed from studying population-based cohorts from Europe, North America, Asia and Australia

It's an openly available fracture risk calculator used to estimate the probability of an individual sustaining an osteoporotic fracture over next 10 years.

It is based on assessment of some important clinical risk factors and BMD (T-score) at femoral neck.





Is fracture healing in osteoporosis normal?







M.S [Ortho], DNB, MNAMS
Dip. SICOT [Belgium]
FNB [Sports Medicine]
Fellowship in MIA, Athens [SICOT]

